Browse the evidence

Plasma IL-15 protein levels increase acutely after resistance exercise but do not change chronically with training and are not associated with variability in muscle responses.

Measuring blood IL-15 levels is not a useful predictor of who will gain muscle from resistance training. Focus on consistent training and nutrition rather than trying to manipulate circulating IL-15 levels.

Loss of the circadian clock gene Bmal1 in skeletal muscle causes systemic glucose intolerance and hyperglycemia by impairing insulin-stimulated glucose uptake and reducing GLUT4 expression.

Maintaining a consistent sleep-wake cycle is critical for metabolic health. Your skeletal muscles rely on their internal circadian clock to efficiently process glucose. Disrupting this rhythm (e.g., through irregular sleep or shift work) can impair insulin sensitivity and glucose tolerance, contributing to higher blood sugar levels and increased diabetes risk.

Higher levels of perceived loneliness are associated with increased objective sleep fragmentation, independent of sleep duration, negative affect, and demographic factors.

If you feel lonely, your sleep may be breaking up into more fragments, even if you are in bed for the usual amount of time. This is a biological stress response to feeling unsafe socially, not just a mood issue. Focus on creating a sense of security and connection, as this may help restore sleep continuity more effectively than just trying to extend total sleep time.

Insulin resistance (IR) fundamentally alters the association between specific lipid subclasses and clinical health markers, causing lipid profiles to diverge significantly from those seen in insulin-sensitive (IS) individuals.

If you have insulin resistance, standard lipid markers (like LDL/HDL ratios) may not predict your health risks the same way they do for healthy people. Your lipid profile's relationship with inflammation and blood sugar changes. Relying solely on standard lipid panels without assessing insulin sensitivity (e.g., fasting insulin, HOMA-IR, or SSPG) may miss critical metabolic risks.

Pharmacological agents that induce browning of white adipose tissue (WAT) or activate brown fat can improve glucose tolerance and insulin sensitivity independent of weight loss.

Improving your metabolic health doesn't always require weight loss. Activating your brown fat through methods like cold exposure can directly improve how your body handles glucose and insulin, offering benefits even if your weight stays the same.

Women exhibit higher skeletal muscle expression of GRB10 and ACVR2B compared to men, which may contribute to smaller muscle mass by inhibiting IGF-1 signaling and increasing myostatin activity.

This research highlights a biological basis for why women, on average, have less muscle mass than men, potentially due to higher levels of specific genes (GRB10 and ACVR2B) that inhibit muscle growth signals. For women, this means that building muscle may require specific attention to resistance training to overcome these inherent signaling constraints, rather than assuming equal ease of growth compared to men.

Carrying a high genetic burden of obesity-risk variants (FTO, SH2B1, MTCH2, MC4R, NEGR1, GNPDA2) causally increases total, abdominal, and gynoid adipose mass, which in turn drives a significantly higher risk of type 2 diabetes.

Your genes can make you heavier and increase your diabetes risk, but they don't dictate your fate. This study shows that genetic risk is largely mediated by body fat. While you can't change your DNA, you can manage the outcome by focusing on maintaining a healthy weight and metabolic health, as the genetic risk is not strong enough to justify ignoring lifestyle factors or relying on genetic tests for clinical decisions.

In morbidly obese individuals, elevated tonic glucose metabolism in the dorsal caudate nucleus mediates abnormal anticipatory reward processing, characterized by heightened connectivity with the amygdala and insula and a failure to activate dorsolateral prefrontal inhibitory control when viewing appetizing food cues.

If you struggle with obesity, your brain may be biologically wired to react more strongly to food cues than others. This isn't a moral failing; it's a neurobiological reality where the 'reward' center (caudate) is overactive and the 'control' center (prefrontal cortex) is underactive. Recognizing this helps shift the strategy from 'trying harder' to 'managing cues' (e.g., removing visual food triggers) to bypass the hyperactive reward pathway.

Metabolic syndrome is associated with a systemic proinflammatory state and increased oxidative stress, characterized by elevated plasma levels of TNFα and IL-6, higher malondialdehyde (lipid peroxidation), and lower plasma superoxide dismutase (SOD) activity.

If you have metabolic syndrome, your body is in a state of chronic low-grade inflammation and oxidative stress. This isn't just 'bad luck'; it's a biological response to visceral fat and metabolic dysfunction. Recognizing this inflammatory state is the first step to understanding why managing weight, blood sugar, and blood pressure is critical for long-term health.

Patients with Metabolic Syndrome exhibit higher antioxidant enzyme activities (Catalase, Glutathione Reductase) and protein levels in Peripheral Blood Mononuclear Cells (PBMCs) compared to those without MetS, likely due to a pre-activated state of immune cells.

Your immune cells are working overtime to fight the oxidative stress caused by metabolic syndrome. This is why your body might have higher levels of certain protective enzymes in your white blood cells. It's a sign of your body trying to protect itself, but it also indicates that your immune system is chronically activated, which is a risk factor for long-term health issues.

Leptin and insulin act as redundant but complementary adiposity signals to the central nervous system (CNS), specifically the ventral hypothalamus, to regulate long-term body fat stores by modulating neuropeptide expression (NPY/AgRP and POMC/CART).

Your body uses hormones like leptin and insulin to defend a specific body fat level. When you lose weight, these signals drop, triggering hunger and reducing energy expenditure to regain the lost fat. Sustainable weight management requires understanding that this is a biological defense mechanism, not just a lack of willpower.

CNS insulin action is dependent on intact leptin signaling, and leptin's effects on energy expenditure are mediated through melanocortin receptors (specifically MC4R).

Treating obesity often requires addressing the brain's downstream response (melanocortin system), not just the upstream hormones. If your body is resistant to leptin or insulin, targeting the final common pathway (like MC4R) might be more effective.

High-fat diets increase serum lipopolysaccharide (LPS) levels (metabolic endotoxemia) by increasing chylomicron transport, decreasing gut barrier integrity, and reducing alkaline phosphatase activity, leading to systemic low-grade inflammation.

High-fat diets can compromise your gut barrier, allowing bacterial toxins (LPS) to enter your bloodstream. This triggers inflammation, which is linked to obesity and metabolic syndrome. To mitigate this, focus on diets that support gut barrier integrity, such as those rich in prebiotics, which have been shown to improve gut barrier function and reduce endotoxemia.

SGLT2 inhibition (canagliflozin) reduces adiposity and activates lipolysis exclusively through FGF21-dependent mechanisms, while its effects on lipid oxidation, ketogenesis, and hepatic steatosis reduction are FGF21-independent.

SGLT2 inhibitors reduce body fat by triggering a hormonal signal (FGF21) that activates fat burning (lipolysis). This process is distinct from simple calorie restriction and requires the presence of FGF21 to effectively reduce fat mass.

HIV protease inhibitor (PI) therapy causes lipodystrophy in HIV-infected patients, characterized by peripheral fat loss and truncal fat accumulation, along with metabolic abnormalities including insulin resistance and dyslipidemia.

If you are taking HIV protease inhibitors, be aware that you may experience changes in body fat distribution (loss in face/limbs, gain in abdomen/neck) and metabolic issues like insulin resistance. Regular monitoring of lipids and glucose is recommended. Do not stop your medication due to these changes without consulting your doctor, as the benefits of HIV suppression usually outweigh the side effects.

Pro-inflammatory cytokines IL-1beta and TNF-alpha are somnogenic; their expression increases with waking activity and sleep deprivation, and they promote non-rapid-eye movement (NREM) sleep and slow-wave activity (SWA).

Prioritize sleep hygiene not just for rest, but to regulate inflammation. Chronic wakefulness or poor sleep increases pro-inflammatory cytokines like IL-1beta and TNF-alpha, which can disrupt sleep architecture and overall health. Managing inflammation through lifestyle may improve sleep, and good sleep helps manage inflammation.

The NLRP3 inflammasome is a critical mediator of sleep regulation; its activation leads to the production of IL-1beta and IL-18, which promote NREM sleep and slow-wave activity.

Understanding that sleep loss activates the NLRP3 inflammasome suggests that chronic sleep deprivation may fuel a cycle of inflammation. Breaking this cycle by improving sleep may reduce inflammasome activity.

Circadian rhythm disruption is associated with increased morbidity risk for inflammatory diseases, including cardiovascular disease, cancer, and metabolic disease.

Maintaining a regular sleep-wake cycle is crucial for long-term health, as disrupting your circadian rhythm increases the risk of inflammatory diseases like heart disease and cancer.

In morbidly obese humans, insulin resistance is associated with significantly lower AMPK activity and higher oxidative stress (protein carbonylation) in adipose tissue compared to insulin-sensitive obesity, regardless of fat depot.

For morbidly obese individuals, achieving weight loss is a step, but metabolic health (insulin sensitivity) is distinct. Research suggests that insulin-resistant obesity involves lower AMPK activity and higher oxidative stress in fat tissue. While this paper is observational, it highlights that metabolic health is not just about weight but about how fat tissue functions at a molecular level. Interventions that improve AMPK activity (like exercise) may be crucial for improving insulin sensitivity beyond just weight loss.

Gene expression changes in adipose tissue of insulin-resistant obese individuals are depot-specific, whereas AMPK activity and oxidative stress are uniform across depots.

Fat tissue is not uniform. In insulin-resistant obesity, some molecular markers (like oxidative stress) are high everywhere, but the genes being turned on or off depend on where the fat is stored (e.g., belly vs. under skin). This complexity means treatments might need to target specific fat depots or understand that 'fat' is not a single organ with a single behavior.

Lipoprotein lipase (LPL) is not strictly necessary or sufficient for normal fat deposition in white adipose tissue; downstream regulation of fatty acid uptake and esterification (mediated by insulin and acylation-stimulating protein) is the primary determinant of fat storage.

Do not assume that strategies targeting Lipoprotein Lipase (LPL) activity alone will effectively change body fat levels. Fat storage in adipose tissue is primarily controlled by what happens *after* LPL releases fatty acids—specifically, how insulin and other factors drive those fatty acids back into fat cells (esterification). If you increase LPL activity without ensuring these downstream storage pathways are active, you may simply circulate more fatty acids rather than storing them.

Hyperinsulinemia in obese PCOS women is primarily driven by reduced hepatic insulin extraction and skeletal muscle insulin resistance, rather than solely by increased pancreatic insulin secretion.

High insulin levels in PCOS are not just because your pancreas is working too hard; your liver is also clearing insulin less efficiently, and your muscles are resisting its effects. This combination leads to high circulating insulin, which can further drive androgen production and weight gain.

Obesity in postmenopausal women increases breast cancer risk and recurrence through hormonal mechanisms, specifically elevated estrone, estradiol, insulin, and IGF-1 levels, and reduced sex hormone-binding globulin (SHBG).

For postmenopausal women, excess body fat is not just a storage issue but a hormonal one. Fat tissue produces estrogen and affects insulin/IGF-1 levels, which can fuel breast cancer growth. Reducing body fat may help normalize these hormone levels, potentially lowering the risk of cancer progression.

Ghrelin is the only known orexigenic gut hormone, and its levels are inversely correlated with body mass index, with obese subjects showing a less marked drop in plasma ghrelin after meal ingestion.

Ghrelin is the 'hunger hormone,' and its levels are lower in obese individuals. However, obese people have a blunted response to meals, meaning their ghrelin doesn't drop as much as it should, potentially contributing to overeating.